NASDAQ · CSBR
Healthcare · Biotechnology
$4.77
Down-$0.15 (-3.05%)
Updated Sep 16, 2026, 10:12 AM
SID Score
2.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
CSBR closed at $4.77 after 20 trading sessions, down 6.29% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $4.8546 | $5.0587 | $4.64 | $4.77 | 30.18K |
| Sep 14, 2026 | $5.00 | $5.01 | $4.92 | $4.92 | 1.8K |
| Sep 11, 2026 | $5.17 | $5.23 | $5.00 | $5.10 | 10.11K |
| Sep 10, 2026 | $5.19 | $5.2691 | $5.05 | $5.0955 | 14.58K |
| Sep 9, 2026 | $4.95 | $5.15 | $4.85 | $5.01 | 28.8K |
| Sep 8, 2026 | $5.11 | $5.21 | $5.05 | $5.05 | 15.29K |
| Sep 4, 2026 | $5.2817 | $5.41 | $5.06 | $5.22 | 10.95K |
| Sep 3, 2026 | $5.2794 | $5.51 | $5.16 | $5.28 | 11.81K |
| Sep 2, 2026 | $5.1499 | $5.2399 | $5.00 | $5.15 | 9.24K |
| Sep 1, 2026 | $5.06 | $5.06 | $5.00 | $5.00 | 2.05K |
| Aug 31, 2026 | $5.015 | $5.0208 | $4.97 | $4.995 | 744.7 |
| Aug 28, 2026 | $5.10 | $5.10 | $4.93 | $4.93 | 5.14K |
| Aug 27, 2026 | $4.895 | $5.02 | $4.87 | $5.02 | 4.4K |
| Aug 26, 2026 | $4.94 | $4.95 | $4.85 | $4.92 | 4.39K |
| Aug 25, 2026 | $4.91 | $4.98 | $4.91 | $4.98 | 2.45K |
| Aug 24, 2026 | $5.07 | $5.135 | $4.855 | $4.97 | 9.31K |
| Aug 21, 2026 | $5.24 | $5.24 | $4.9126 | $4.9601 | 8.15K |
| Aug 20, 2026 | $4.83 | $5.18 | $4.83 | $5.18 | 7.97K |
| Aug 19, 2026 | $5.23 | $5.23 | $4.9201 | $4.94 | 10.38K |
| Aug 18, 2026 | $5.2388 | $5.335 | $5.04 | $5.09 | 11.04K |
The latest Smart Investors Daily articles mentioning CSBR.
CSBR research
Company profile and research snapshot.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 12, 2025 | Craig-Hallum | Buy | — |
| Dec 12, 2024 | Craig-Hallum | Buy | — |
| Sep 12, 2024 | Craig-Hallum | Buy | — |
| Mar 13, 2024 | Craig-Hallum | Hold | — |
| Sep 22, 2023 | Roth MKM | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 4, 2026
HACKENSACK, NJ / ACCESS Newswire / September 4, 2026 / (CSBR), a global leader in clinically relevant oncology research models and translational solutions, will report its financial and operational results for the quarter ended July 31, 2026, on Thursday, September 10, 2026, after market close. The company will host a conference call to discuss the results that day at 4:30 P.
Yahoo · Sep 1, 2026
New molecular imaging capabilities connect longitudinal radiopharmaceutical uptake with biodistribution, efficacy and clinically annotated PDX tumor biology in a single, U.-based workflowHACKENSACK, NJ / ACCESS Newswire / September 1, 2026 / , a leading provider of translational oncology research solutions, today announced the expansion of its integrated radiopharmaceutical development platform with new in-house SPECT/CT imaging capabilities.
Benzinga · Sep 1, 2026
New molecular imaging capabilities connect longitudinal radiopharmaceutical uptake with biodistribution, efficacy and clinically annotated PDX tumor biology in a single, U.S.-based workflowHACKENSACK, NJ / ACCESS
Yahoo · Jul 30, 2026
Champions Oncology reports fourth-quarter fiscal 2026 growth as revenue gains, margin improvement and operational initiatives support progress.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CSBR.
